Aspen Pharmacare Holdings Limited (OTCMKTS:APNHY - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,100 shares, a growth of 950.0% from the December 15th total of 200 shares. Based on an average trading volume of 900 shares, the short-interest ratio is presently 2.3 days.
Aspen Pharmacare Stock Down 9.1 %
Shares of OTCMKTS APNHY traded down $0.85 during trading hours on Monday, hitting $8.41. The company had a trading volume of 490 shares, compared to its average volume of 1,445. The company has a current ratio of 1.81, a quick ratio of 1.07 and a debt-to-equity ratio of 0.30. The firm's 50 day moving average is $9.39 and its 200-day moving average is $10.99. Aspen Pharmacare has a 1-year low of $8.26 and a 1-year high of $13.69.
Aspen Pharmacare Company Profile
(
Get Free Report)
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.
Read More
Before you consider Aspen Pharmacare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aspen Pharmacare wasn't on the list.
While Aspen Pharmacare currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.